Nanjing Bioheng Biotech Co., Ltd.
Clinical trials sponsored by Nanjing Bioheng Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune reset: CAR-T cells take on lupus and more Results expected Dec 2026 (estimated)
- Immune reset: CAR-T therapy targets lupus, MS, and more Results expected Jan 2027 (estimated)
- Experimental CAR-T therapy takes on lupus and more Results expected Jul 2027 (estimated)
-
Experimental CAR-T therapy takes on lupus and more
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Immune reset: CAR-T cells take on lupus and more
Disease control Recruiting nowThis early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Immune reset: CAR-T therapy targets lupus, MS, and more
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC